INVENTORIES

9 Months Ended

Sep. 30, 2024

INVENTORIES [Abstract]

INVENTORIES

3. INVENTORIES

The following table provides the components of inventories:

	September 30, 2024		December 31, 2023
	(In thousands)
Raw materials	$	55,246	$	52,999
Work-in-process		53,482		49,621
Finished goods		63,073		70,286
Total inventories	$	171,801	$	172,906

Raw materials includes plasma and other materials expected to be used in the production of ASCENIV, BIVIGAM and Nabi-HB. These materials will be consumed in the production of goods expected to be available for sale or otherwise have alternative uses that provide a probable future benefit.

Work-in-process inventory primarily consists of bulk drug substance and unlabeled filled vials of the Company’s immunoglobulin products.

Finished goods inventory is comprised of immunoglobulin product inventory and related intermediates that are available for commercial sale, as well as plasma collected at the Company’s plasma collection centers that is expected to be sold to third-party customers.